{
    "name": "adefovir",
    "comment": "Rx",
    "other_names": [
        "adefovir dipivoxil",
        "Hepsera"
    ],
    "classes": [
        "Hepatitis B/Hepatitis C Agents",
        "Hepatitis B",
        "NRTIs"
    ],
    "source": "https://reference.medscape.com/drug/adefovir-dipivoxil-hepsera-342635",
    "pregnancy": {
        "common": [
            "There is pregnancy exposure registry that monitors pregnancy outcomes in women exposed during pregnancy; healthcare providers are encouraged to register patients by calling Antiretroviral Pregnancy Registry (APR) at 1-800-258- 4263",
            "Prospective pregnancy data from APR are not sufficient to adequately assess risk of birth defects, miscarriage or adverse maternal or fetal outcomes; adefovir disoproxil (ADV) use during pregnancy has been evaluated in a limited number of individuals reported to APR and the number of exposures to adefovir is insufficient to make a risk assessment compared to a reference population; estimated background rate for major birth defects is 2.7% in the U.S. reference population of Metropolitan Atlanta Congenital Defects Program (MACDP); estimated rate of miscarriage is not reported in APR; all pregnancies have a background risk of birth defect, loss, or other adverse outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies with oral ADV, no adverse developmental effects were observed at exposures (Cmax) 23 times higher in rats and 40 times higher in rabbits than those at recommended human dose (RHD)"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "It is not known whether adefovir is present in human breast milk, affects human milk production, or has effects on breastfed infant",
            "The developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Severe acute exacerbations of hepatitis reported following discontinuing drug; monitor hepatic function",
                "Chronic use may result in nephrotoxicity in patients with renal impairment or in those at risk of renal dysfunction; dose adjustment may be required",
                "Resistance to HIV NRTIs may emerge in patients with chronic hepatitis B in whom HIV infection is unrecognized or untreated",
                "Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, reported with nucleoside analogs alone or in combination with other antiretrovirals; obesity and prolonged nucleoside exposure may be risk factors"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Concurrent use with products containing tenofovir disoproxil fumarate or tenofovir alafenamide"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Discontinuation may result in severe acute exacerbation of hepatitis B",
                "Patients who discontinue treatment: Monitor hepatic function for several months",
                "Patients with renal dysfunction: Risk of nephrotoxicity (monitor and adjust dose accordingly)",
                "Coadministration with drugs that reduce renal function may increase adefovir serum concentration",
                "Do not administer with tenofovir (additive toxicity)",
                "May increase HIV resistance in untreated patients who are HIV+",
                "Risk of lactic acidosis, severe hepatomegaly with steatosis",
                "To monitor fetal outcomes, Pregnancy Registry established: 1-800-258-4263"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "bacitracin",
            "description": {
                "common": "adefovir and bacitracin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Avoid concurrent use of bacitracin with other nephrotoxic drugs"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "pretomanid will increase the level or effect of adefovir by  Other (see comment). Avoid or Use Alternate Drug. In vitro studies demonstrated that pretomanid significantly inhibits OAT3; monitor for increased adverse effects and consider dosage reduction for OAT3 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "adefovir, tenofovir DF.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Enhanced nephrotoxicity. Avoid coadministration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amikacin",
            "description": {
                "common": "adefovir and amikacin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "adefovir and amphotericin B deoxycholate both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabozantinib",
            "description": {
                "common": "adefovir will increase the level or effect of cabozantinib by  Other (see comment). Use Caution/Monitor. MRP2 inhibitors increase cabozantinib toxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capreomycin",
            "description": {
                "common": "adefovir and capreomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "adefovir and carboplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cidofovir",
            "description": {
                "common": "adefovir and cidofovir both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "adefovir and cisplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "contrast media (iodinated)",
            "description": {
                "common": "adefovir and contrast media (iodinated) both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "adefovir and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "adefovir and elvitegravir/cobicistat/emtricitabine/tenofovir DF both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "adefovir increases levels of emtricitabine by Other (see comment). Use Caution/Monitor. \nComment: Coadministration of emtricitabine with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of emtricitabine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ioversol",
            "description": {
                "common": "adefovir and ioversol both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "adefovir and neomycin PO both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "adefovir and oxaliplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peramivir",
            "description": {
                "common": "adefovir increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptozocin",
            "description": {
                "common": "adefovir and streptozocin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "adefovir and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teicoplanin",
            "description": {
                "common": "adefovir and teicoplanin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, adefovir.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acyclovir",
            "description": {
                "common": "acyclovir and adefovir both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cephaloridine",
            "description": {
                "common": "adefovir and cephaloridine both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colistin",
            "description": {
                "common": "adefovir and colistin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "foscarnet",
            "description": {
                "common": "adefovir and foscarnet both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gentamicin",
            "description": {
                "common": "adefovir and gentamicin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "ibuprofen increases levels of adefovir by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "ibuprofen IV increases levels of adefovir by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methoxyflurane",
            "description": {
                "common": "adefovir and methoxyflurane both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paromomycin",
            "description": {
                "common": "adefovir and paromomycin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentamidine",
            "description": {
                "common": "adefovir and pentamidine both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "adefovir and polymyxin B both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "streptomycin",
            "description": {
                "common": "adefovir and streptomycin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tobramycin",
            "description": {
                "common": "adefovir and tobramycin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vancomycin",
            "description": {
                "common": "adefovir and vancomycin both increase  nephrotoxicity and/or ototoxicity. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hematuria",
            "percent": "11"
        },
        {
            "name": "vs",
            "percent": "10"
        },
        {
            "name": "in placebo",
            "percent": "13"
        },
        {
            "name": "treated",
            "percent": "14"
        },
        {
            "name": "Asthenia",
            "percent": "25"
        },
        {
            "name": "vs",
            "percent": "5"
        },
        {
            "name": "placebo",
            "percent": "4"
        },
        {
            "name": "Hepatitis exacerbation",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Flatulence",
            "percent": "9"
        },
        {
            "name": "Diarrhea",
            "percent": "1-10"
        },
        {
            "name": "Dyspepsia",
            "percent": "1-10"
        },
        {
            "name": "Headache",
            "percent": "5-9"
        },
        {
            "name": "Rash",
            "percent": "6-8"
        },
        {
            "name": "Pruritus",
            "percent": "5"
        },
        {
            "name": "Dyspepsia",
            "percent": "2-3"
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "Increased AST",
            "percent": null
        },
        {
            "name": "ALT",
            "percent": null
        },
        {
            "name": "Abnormal liver function",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Renal insufficiency",
            "percent": null
        },
        {
            "name": "Increased serum Cr",
            "percent": null
        },
        {
            "name": "Hypophosphatemia",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hypophosphatemia",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Musculoskeletal system and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Myopathy",
            "percent": null
        },
        {
            "name": "osteomalacia",
            "percent": null
        },
        {
            "name": "manifested as bone pain and may contribute to fractures",
            "percent": null
        },
        {
            "name": "both associated with proximal renal tubulopathy",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Fanconi syndrome",
            "percent": null
        },
        {
            "name": "proximal renal tubulopathy",
            "percent": null
        }
    ]
}